CoreWeave vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? CoreWeave trades at $82.39 (market cap $44.99B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: CoreWeave is far larger — about 19.8× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, CoreWeave nearer its low. Which is the better fit depends on your goals.
| CRWV | SLS | |
|---|---|---|
Market Cap | $44.99B | $2.27B |
Volume | 41,993,776 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $143.08 | $15.46 |
52-Week Low | $60.82 | $1.39 |
Typical Hold Time | 7 Days | — |
Enterprise Value | $91.06B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
CRWV trades at $82.08, down 7.2% amid a broader AI stock sell-off. The technical picture is bearish, with price below key resistance levels. Fundamentally, the company shows strong revenue growth but deep losses, with a net income margin of -25.4% in 2026. A massive $104 billion backlog signals high demand, yet expansion requires significant debt and equity financing, increasing financial risk.
The outlook is polarized: high growth potential from AI infrastructure demand contrasts with substantial execution and financial risks. Analyst consensus is bullish with a $147.57 price target, but investors face volatility from debt-funded expansion and competitive pressures. The stock's trajectory hinges on converting its backlog to profitable revenue.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →